{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:55:22Z","timestamp":1777866922462,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T00:00:00Z","timestamp":1255046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T00:00:00Z","timestamp":1255046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologica"],"abstract":"<jats:p>Apoprotein, lipoprotein and lipid parameters of 36 normolipidemic subjects (23 males, mean age 22.7 \u00b1 7.6 years; 13 females, mean age 26.2 \u00b1 9.8 years) receiving oral isotretinoin (mean daily dose 0.73 \u00b1 0.26 mg\/kg body weight) for nodulocystic acne (n = 18), severe acne papulopustulosa (n = 15), gram-negative folliculitis (n = 2) and papulopustular rosacea (n = l) were monitored before and during isotretinoin therapy at biweekly intervals over a period of 14.6 \u00b1 5.6 weeks. Pretreatment values of mean plasma triglycerides increased significantly (p &lt; 0.001) from 81.8 \u00b1 31.9 mg\/dl to 112.4 \u00b1 38.7 mg\/dl (47.4%) during isotretinoin treatment. With respect to the mean percent increase of plasma triglycerides from pretreatment levels, patients were classified as nonresponders ( &lt; 10% triglyceride increase), responders ( &gt; 10% &lt; 50% triglyceride increase) and hyperresponders ( &gt; 50% triglyceride increase), revealing a distribution of 25.0, 36.1 and 38.9%, respectively. Isotretinoin treatment had no influence on the isoelectric focusing pattern of apoprotein E isoforms and C apoproteins. In particular, apoprotein C-II, the cofactor of lipoprotein lipase, was not affected. No correlation between apoprotein E phenotypes (2\/3, 3\/3, 3\/4) and the mean plasma triglyceride increase could be demonstrated. Apoprotein B-48, a marker of chylomicrons and atherogenic chylomicron remnants, could not be detected by SDS-PAGE. On the other hand in 21.0% of patients with preexisting mean lipoprotein Lp(a) levels of 18.1 \u00b1 12.9 mg\/dl a moderate increase of atherogenic Lp(a) to mean levels of 37.0 \u00b1 22.0 mg\/dl was observed. Pretreatment values of very-low-density lipoprotein (VLDL) apoprotein (apo) B (7.5 \u00b1 2.0 mg\/dl), low-density lipoprotein apo B (67.3 \u00b1 17.5 mg\/dl) and total plasma apo B (76.6 \u00b1 19.0 mg\/dl) increased significantly to levels of 10.3 \u00b1 2.4 mg\/dl (p &lt; 0.001), 75.7 \u00b1 15.8 mg\/dl (p &lt; 0.10) and 85.9 \u00b1 17.7 mg\/dl (p &lt; 0.05), respectively. As lipoprotein lipase and hepatic lipase activities have been shown to be unaffected by isotretinoin treatment, our data support the hypothesis that isotretinoin induces hepatic oversecretion of VLDL, a condition resembling type IV hyperlipidemia in diabetics, familial hypertriglyceridemia or familial combined hyperlipidemia.<\/jats:p>","DOI":"10.1159\/000248880","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T13:46:30Z","timestamp":1255527990000},"page":"158-168","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of Apoprotein Metabolism and Atherogenic Lipoproteins during Oral Isotretinoin Treatment"],"prefix":"10.1159","author":[{"given":"B.","family":"Melnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Plewig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,10,9]]},"container-title":["Dermatologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/248880","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000248880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:35:17Z","timestamp":1777541717000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000248880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000248880","archive":["Portico"],"relation":{},"ISSN":["0011-9075","2571-7197"],"issn-type":[{"value":"0011-9075","type":"print"},{"value":"2571-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,9]]}}}